I am puzzled by your statement that less then 8 percent of total pharmaceutical sales is reinvested in R&D. As you know, that number for the innovative pharmaceutical industries is usually around 15–20%. If you include in the total sales also generic sales coming from companies that by definition do not invest in R&D, that 8 percent does not mean much. In that way one could also include sales from wholesalers and pharmacists, which would further lower that percentage even further, but does not make sense of course. Reinvestment in R&D should be only be calculated for those industries that actually invest in R&D, it seems to me.
Henk Jan Out, professor of pharmaceutical medicine, The Netherlands